Pernicious Anemia With Neurologic Symptoms: The Danger Was Never Folate
A single patient, with numbness and gait changes that argue for treating today. The disagreement isn't whether she has a B12 problem — it's whether folate can be given safely alongside it or must wait.
Eleanor V. moved in with her daughter's family five months ago after a fall in her own kitchen made living alone feel too uncertain, a decision she made peace with faster than she expected to after forty years as a seamstress for a local tailoring shop, work she'd only stopped once her hands could no longer manage the fine stitching. Over the past three months she has noticed her fingers going numb while she tries to knit, a hobby she took up specifically to keep her hands busy after retiring, and her daughter has watched her gait grow noticeably less steady on the stairs, twice needing to steady herself against the railing on steps she has climbed daily for months without trouble.
On exam, she has diminished vibration sense at both ankles, impaired proprioception on toe position testing, and a positive Romberg sign, alongside a smooth, mildly beefy-red tongue she hadn't mentioned as a symptom herself. Her labs show a macrocytic anemia with a hemoglobin of 9.8 and an MCV of 112, a low serum B12, and a folate level sitting at the low end of normal — not clearly deficient, but not comfortably reassuring either.
Her progressive numbness and gait change raise real concern for subacute combined degeneration, the specific dorsal-column and corticospinal-tract spinal cord injury B12 deficiency can cause, which makes the usual instinct toward efficiency — replete both vitamins together while confirmatory testing is pending — a genuinely dangerous shortcut in her particular case. Folate can correct the megaloblastic marrow picture and normalize the blood count even when the underlying driver is unrecognized B12 deficiency, since folate feeds the same DNA-synthesis pathway downstream of the cobalamin-dependent step B12 actually catalyzes — which historically allowed the neurologic injury to continue advancing, unmasked, behind blood counts that looked reassuring. The British Society for Haematology guidelines on cobalamin and folate disorders, published by Devalia and colleagues in 2014, address this directly: no randomized trial exists or is likely to, and the instruction rests on the physiology plus decades of case reports — treat the B12 first, and never give folate as sole therapy where B12 deficiency has not been excluded.
The danger was never folate — it was folate alone
Given her actively progressing neurologic exam, I wouldn't wait on methylmalonic acid or intrinsic factor antibody results before starting B12 — that confirmatory testing is for documenting the diagnosis, not for deciding whether to treat a patient with findings this concerning for subacute combined degeneration. Start B12 today.
What I would hold, at least until B12 replacement is clearly underway, is folate given alone — that specific combination, unrecognized B12 deficiency treated only with folate, is the classic setup for correcting the blood count while the neurologic injury keeps advancing unmasked.
I agree completely on not delaying for confirmatory labs, and on never giving folate alone here. I'd go one step further on the practical plan: give B12 and folate together, starting the same day, rather than sequencing folate to follow B12 by some interval — there's no clinical reason to withhold folate itself once B12 replacement is already underway alongside it, and her folate is genuinely low-normal, not clearly normal.
The danger was always folate ALONE unmasking B12 deficiency, not folate given concurrently with adequate B12 — conflating those two scenarios is a common but avoidable error.
Agreed: B12 and folate started together the same day, with confirmatory intrinsic factor antibody and methylmalonic acid testing sent but not awaited before treating.
Not agreed: how quickly to expect her gait and numbness to improve, and how to counsel her daughter about that timeline — the hematologist was more cautious about the odds of full neurologic recovery given how long her symptoms had progressed before diagnosis.